ATTACHMENT A.3_COSMOS Milestone and Payment Table.xlsx
XLSX spreadsheet 22 KB Posted
- Attached to
- ARPA-H Comprehensive Organ System Modeling in Outer Space (COSMOS) Innovative Solutions Opening
- Solicitation number
- ARPA-H-SOL-26-165
About this file
This file is a milestone and payment table template for the ARPA-H Comprehensive Organ System Modeling in Outer Space (COSMOS) initiative. The document outlines mandatory deliverables and milestones organized by phase and task structure, with required submissions organized by month and quarter. Key Phase 1 deliverables include material transfer agreements with commercial service flight and hardware providers (Month 2, Q1); a commercialization plan describing how tissue aging rates in space (TARIS) exceeding tissue aging rates on Earth (TAROE) could be commercialized (Month 3, Q1); a collaboration plan and timeline with CSP-Technical teams (Month 5, Q2); and a Data Management and Sharing Plan revision if needed (Month 1, Q1). Additional Phase 1 requirements include quantification of tissue aging rates using microphysiological systems (MPSs) for target organs, development of licensable datasets combining terrestrial and Low Earth Orbit (LEO) twin data, commercial CSP hardware integration plans, and final TARIS:TAROE models.
By the end of Phase 1, teams must establish signed contractual partnerships and licensing agreements with at least one commercial pharmaceutical discovery or manufacturing partner with drugs applicable to the organ type showing the greatest TARIS:TAROE differential. Phase 2 deliverables include disease model development and scaling plans, credible and reproducible disease models using microgravity-leveraged MPS technology for novel drug screening, proof-of-concept high-throughput drug testing demonstrating identification of drugs that prevent or reverse age-related tissue dysfunction, Phase 2 commercial partnership plans, and TARIS-TAROE models tables. The document serves as a structured template for proposers to populate with specific task titles, milestone descriptions, quantitative metrics, and cost allocations across the defined start and end quarters for each phase.
View the file
Other files
| File | Type | Posted |
|---|---|---|
| ARPA-H-SOL-26-165_COSMOS_QA_Set_2_2026-09-25.pdf | ||
| ARPA-H-SOL-26-165_COSMOS_ISO_Amendment 02.pdf | ||
| ARPA-H-SOL-26-165_COSMOS_QA_Set_1_2026-09-21.pdf | ||
| ARPA-H-SOL-26-165_COSMOS_ISO_Amendment 01.pdf | ||
| Attachment E_COSMOS Administrative and National Policy Requirements.docx | DOCX document | |
| Attachment D_COSMOS Cost Proposal Template.xlsx | XLSX spreadsheet | |
| ATTACHMENT A.2_Task Description Document Model.docx | DOCX document | |
| ATTACHMENT C COSMOS Schedule.xlsx | XLSX spreadsheet | |
| ATTACHMENT A.1_Technical & Management Proposal Model (VOL I).docx | DOCX document | |
| ATTACHMENT B_COSMOS Eligibility and Conformance Certification Sheet.docx | DOCX document | |
| ARPA-H-SOL-26-165_COSMOS_ISO.docx | DOCX document |
Show all 11
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
Mandatory Deliverables
| Item | Month Due | Q due | Description |
| Material Transfer agreement with Commercial Service Flight provider | 2 | 1 | |
| Material Transfer agreement with Commercial Service Hardware provider | 2 | 1 | |
| Commercializaion Plan | 3 | 1 | Teams must submit a high-level commercialization plan describing how an MPS age bracket which exhibits a tissue aging rate in space (TARIS) is greater than a tissue aging rate on earth (TAROE) could be commercialized. |
| Collaboration plan and timeline CSP-Technical teams | 5 | 2 | |
| Data Management and Sharing Plan Revision (if needed) | 1 | 1 | |
| Quantification of Tissue Aging Rate in Space (TARIS) using microphysiological systems (MPSs) (and potentially organoids as well) for target organ | |||
| Licensable data set comprising the Terrestrial Arm data and LEO Twin Data | |||
| Commercial CSP Hardware integration plan with MPSs for timely spaceflight | |||
| Final TARIS:TAROE model of tissue changes in LEO | |||
| Signed, contractual partnership and licensing agreement with AT LEAST one commercial pharmaceutical discovery/ manufacturing partner that has drugs of interest that are applicable to the organ type with the greatest TARIS:TAROE | |||
| By the end of phase 1, each team must have a signed, contractual partnership and licensing agreement with AT LEAST one commercial pharmaceutical discovery/manufacturing partner that has drugs of interest that are applicable to the accelerated organ type | |||
| Phase II Disease Model and Scaling Plan | Credible and reproducible plan to develop relevant disease model(s) within the selected organ based on state of the art, | ||
| · Credible, reproducible disease model(s) of tissues where TARIS > TAROE from Phase I successfully used in coordination with commercial partner(s) for novel drug screening | |||
| · Demonstration of proof-of-concept high throughput drug testing using microgravity-leveraged MPS models of aging to identify drugs that can prevent and/or reverse age-related tissue dysfunction and/or disease | |||
| Commercial CSP Hardware integration with MPSs for timely spaceflight | |||
| Phase II Commercial Partenrship Plan | |||
| TARIS-TAROE Models |
Table
| Phase | Category | Task # | Milestone # | Task/Milestone Title | Milestone Description and Metrics | Start Qrt | End Qrt | Cost | |
| Phase 1 | Task 1 | - | Task Title | ||||||
| (include the PI and organization performing the work in parantheses) | Task Description: Include a brief description of the proposed work. | ||||||||
| Phase 1 | Task 1 | M1.1 | Milestone Title | ||||||
| (include the PI and organization performing the work in parantheses) | Milestone Description: Include a brief description of the proposed work. |
Quantitative Metrics: Provide a list of deliverables and quantitative exit criteria to evaluate the proposed work included in the milestone description.
| Phase 1 | Task 1 | M1.2 | Milestone Title | |
| (include the PI and organization performing the work in parantheses) | Milestone Description: Include a brief description of the proposed work. |
Quantitative Metrics: Provide a list of deliverables and quantitative exit criteria to evaluate the proposed work included in the milestone description.
| Phase 1 | Task 1 | M1.3 | Milestone Title | |
| (include the PI and organization performing the work in parantheses) | Milestone Description: Include a brief description of the proposed work. |
Quantitative Metrics: Provide a list of deliverables and quantitative exit criteria to evaluate the proposed work included in the milestone description.
| Phase 1 | Task 2 | - | - |
| Phase 1 | Task 2 | M2.1 | |
| Phase 1 | Task 2 | M2.2 | |
| Phase 1 | Task 2 | M2.3 | |
| Phase 1 | |||
| Phase 1 | Task 3 | - | |
| Phase 1 | Task 3 | M3.1 | |
| Phase 1 | Task 3 | M3.2 | |
| Phase 1 | Task 3 | ||
| Phase 1 | |||
| Phase 1 | |||
| Phase 1 | |||
| Phase 1 | |||
| Phase 1 | |||
| Phase 1 | |||
| Phase 1 | |||
| Phase 1 | |||
| Phase 1 | |||
| Phase 1 | |||
| Phase 1 | |||
| Phase 1 | |||
| Phase 1 | |||
| Phase 1 | |||
| Phase 1 | |||
| Phase 1 | |||
| Phase 1 | |||
| Phase 2 | |||
| Phase 2 | |||
| Phase 2 | |||
| Phase 2 | |||
| Phase 2 | |||
| Phase 2 | |||
| Phase 2 | |||
| Phase 2 | |||
| Phase 2 | |||
| Phase 2 | |||
| Phase 2 | |||
| Phase 2 | |||
| Phase 2 | |||
| Phase 2 | |||
| Phase 2 | |||
| Phase 2 | |||
| Phase 2 | |||
| Phase 2 | |||
| Phase 2 | |||
| Phase 2 | |||
| Phase 2 | |||
| Phase 2 | |||
| Phase 2 | |||
| Phase 2 | |||
| Phase 2 | |||
| Phase 2 |
File details come from the government source that posted it. Updated .